Pancreatic cancer - Pipeline Insight, 2026

DelveInsight's, "Pancreatic cancer - Pipeline Insight, 2026" report provides comprehensive insights about 170+ companies and 200+ pipeline drugs in Pancreatic cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

• Global coverage

Pancreatic cancer: Understanding

Pancreatic cancer: Overview

Pancreatic cancer is a malignant neoplasm that arises primarily from the ductal epithelial cells of the pancreas, most commonly presenting as pancreatic ductal adenocarcinoma. It is considered one of the most aggressive and lethal cancers, ranking among the leading causes of cancer-related mortality worldwide. The disease is characterized by poor prognosis, with reported 5-year survival rates generally ranging between 5% and 15%, reflecting its highly aggressive nature and late detection. Histologically, the majority of cases are adenocarcinomas, with tumors most frequently originating in the head of the pancreas, although they can also arise in the body and tail.

Pancreatic cancer exhibits metabolic abnormalities and insensitivity to growth-inhibitory pathways. Loss of negative growth constraints is best exemplified by aberrant TGFB signalling, which occurs due to increased expression of TGFB isoforms. Although TGFB is a physiological tumor suppressor, it promotes tumor progression in pancreatic cancer and many other solid tumors by exerting paracrine effects within the tumor microenvironment that lead to enhanced growth and metastasis. TGFB can also directly induce pancreatic cancer cell proliferation by activating non-canonical signalling through mitogen-activated protein kinase (MAPK) phosphorylation, proto-oncogene tyrosine-protein kinase Src (SRC), and AKT phosphorylation, and by upregulating WNT7B expression through canonical SMAD4-dependent mechanisms.

The diagnosis of pancreatic cancer involves a combination of imaging, laboratory tests, and tissue confirmation. Contrast-enhanced CT scans are typically the first-line tool to detect and evaluate pancreatic masses, while MRI and endoscopic ultrasound (EUS) provide further characterization and help guide biopsy. A definitive diagnosis is usually made through histopathological examination of tissue obtained via EUS-guided fine needle aspiration. Tumor markers such as CA 19-9 may support diagnosis and monitoring but are not reliable as standalone tests.

Treatment of pancreatic cancer depends on disease stage, with surgical resection being the only curative option for localized tumors, typically followed by chemotherapy or radiotherapy. In borderline or locally advanced cases, neoadjuvant therapy is used to improve resectability. For advanced or metastatic disease, treatment is mainly palliative, focusing on systemic chemotherapy and supportive care to manage symptoms. For unresectable or metastatic disease, treatment is primarily palliative, involving systemic chemotherapy and supportive care to relieve symptoms and improve quality of life.

"Pancreatic cancer- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pancreatic cancer pipeline landscape is provided which includes the disease overview and Pancreatic cancer treatment guidelines. The assessment part of the report embraces, in depth Pancreatic cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pancreatic cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights:

• The companies and academics are working to assess challenges and seek opportunities that could influence Pancreatic cancer R&D. The therapies under development are focused on novel approaches to treat/improve Pancreatic cancer.

Pancreatic cancer Emerging Drugs Chapters

This segment of the Pancreatic cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Pancreatic cancer Emerging Drugs

• TQB2868: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

TQB2868 injection is a PD-1/TGF-B bifunctional fusion protein independently developed by Chia Tai Tianqing Pharmaceutical Group. It can block the PD-1/PD-L1 pathway and neutralize TGF-B in the tumor microenvironment, exhibiting dual effects of immune checkpoint inhibition and tumor microenvironment remodeling. The combined inhibition of PD-1 and TGF-B signaling can lead to a more effective anti-tumor immune response than inhibition of either pathway alone, thereby improving clinical benefits in anti-tumor treatment. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of pancreatic cancer.

• Trabedersen (OT-101): Oncotelic Inc./ Autotelic Bio Inc.

Trabedersen, also referred as OT-101 is a novel antisense oligodeoxynucleotide (ODN). It is a synthetic 18-mer phosphorothioate oligodeoxynucleotide (S-ODN) complementary to the messenger ribonucleic acid (mRNA) of the human TGF-B2 gene. Cancers overexpress TGF-B, which suppresses host innate immune response to the cancers. Treatment with OT-101 lifts the TGF-B cloaking effect and allows innate or therapeutic immunity to attack and eliminate the cancers. The drug has showed favorable safety and long-term disease control in over half of the treated patients in PDAC. Currently, the drug is being evaluated in the Phase II/III stage of its development for the treatment of pancreatic cancer.

• Antroquinonol: Golden Biotechnology Corp.

Antroquinonol is a small molecule NCE with demonstrated activities both in-vivo and in-vitro against a number of malignancies, infectious diseases and neuro-degenerative diseases. Antroquinonol inhibited Ras and Ras-related GTP-binding protein activation through inhibition of protein isoprenyl transferase activity, leading to activation of autophagy and associated mode of cell death in cancer cells. Additionally, it can be taken orally, providing a convenient treatment option for patients. Antroquinonol has gained recognition for its groundbreaking work in the field of cancer treatment. It has been granted Orphan Drug Designation (ODD) by the FDA for the treatment of Pancreatic Cancer. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of pancreatic cancer.

• Nadunolimab: Cantargia AB

Nadunolimab (CAN04) is an Anti-IL1RAP antibody for treatment of various cancer types. Nadunolimab binds strongly to its target molecule IL1RAP, expressed on tumor cells from many types of cancer. Nadunolimab blocks the signaling of interleukin-1, alpha and beta, thereby limiting tumor development as well as working synergistically with chemotherapy and adding functionality through Antibody-Dependent Cellular Cytotoxicity (ADCC). In June 2025, the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to nadunolimab for for the treatment of patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC) with high expression levels of IL1RAP in combination with gemcitabine and nab-paclitaxel. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of pancreatic cancer.

• MT-601: Marker Therapeutics, Inc.

MT-601 is a promising Multi-Tumor Associated Antigen (multiTAA)-specific T cell therapy developed by Marker Therapeutics for treating advanced or metastatic pancreatic cancer. It is a non-genetically modified therapy that targets six antigens ommonly expressed in pancreatic tumors. Unlike CAR-T therapy, MT-601 is a non-genetically modified T cell product. It targets multiple tumor-associated antigens, which may reduce the risk of immune evasion by the tumor. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of pancreatic cancer.

• fb-PMT: NanoPharmaceuticals

Fb-PMT (NP751) is a novel, potent thyrointegrin antagonist that has shown high effectiveness in preclinical studies for pancreatic cancer, reducing tumor weight and viability by over 90% in mice Fb-PMT works by targeting the thyrointegrin receptor, which is overexpressed on the surface of pancreatic cancer cells and dividing blood vessel cells, inducing anti-angiogenic and anticancer effects. Currently, the drug is being evaluated in the preclinical stage of its development for the treatment of pancreatic cancer.

Pancreatic cancer: Therapeutic Assessment

This segment of the report provides insights about the different Pancreatic cancer drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Pancreatic cancer

There are approx. 170+ key companies which are developing the therapies Pancreatic cancer. The companies which have their Pancreatic cancer drug candidates in the most advanced stage, i.e. Phase III include, Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd., and others.

• Phases

DelveInsight's report covers around 200+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Pancreatic cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Pancreatic cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pancreatic cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pancreatic cancer drugs.

Pancreatic cancer Report Insights

• Pancreatic cancer Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Pancreatic cancer Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions:

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Pancreatic cancer drugs?
• How many Pancreatic cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pancreatic cancer?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Pancreatic cancer therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Pancreatic cancer and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
• Oncotelic Inc
• Golden Biotechnology Corp.
• Cantargia AB
• Marker Therapeutics, Inc.
• NanoPharmaceuticals
• Innovent Biologics /takeda
• Verastem, Inc.
• Autotelic Bio Inc.
• Oncolytics Biotech
• Agenus Inc.
• ONO PHARMACEUTICAL CO., LTD.
• Merck Sharp & Dohme LLC.
• Akeso Biopharma Co., Ltd.
• ImmunityBio, Inc.
• NETRIS Pharma
• Merck & Co., Inc.
• Nihon Medi-Physics Co., Ltd.
• FutureGen Biopharmaceutical (Beijing) Co., Ltd
• Can-Fite Biopharma
• InxMed

Key Products

• TQB2868
• Trabedersen (OT-101)
• Antroquinonol
• Nadunolimab
• MT-601
• fb-PMT
• IBI343
• VS-7375
• ATB-320
• Pelareorep
• Balstilimab
• ONO-7913
• Lenvatinib
• AK154
• HCW9218
• NP137
• ifinatamab deruxtecan (MK-2400)
• patritumab deruxtecan(MK-1022)
• sacituzumab tirumotecan
• NMK89
• FG-M108
• Namodenoson
• IN10018